Literature DB >> 24913829

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.

Lizamma Antony1, Freek van der Schoor, Susan L Dalrymple, John T Isaacs.   

Abstract

INTRODUCTION: Physiologic testosterone continuously stimulates prostate stromal cell secretion of paracrine growth factors (PGFs), which if unopposed would induce hyperplastic overgrowth of normal prostate epithelial cells (PrECs).
METHODS: Lentiviral shRNA stable knock down of c-MYC, β-catenin, or TCF-4 completely inhibits normal (i.e., non-transformed) human PrECs growth. c-MYC enhancer driven reporter expression and growth is inhibited by two chemically distinct molecules, which prevent β-catenin signaling either by blocking TCF-4 binding (i.e., toxoflavin) or by stimulating degradation (i.e., AVX939). Recombinant DKK1 protein at a dose, which inhibits activation of canonical Wnt signaling does not inhibit PrEC growth. Nuclear β-catenin translocation and PrEC growth is prevented by both lack of PGFs or Akt inhibitor-I. Growth inhibition induced by lack of PGFs, toxoflavin, or Akt inhibitor-I is overcome by constitutive c-MYC transcription.
RESULTS: In the presence of continuous PGF signaling, PrEC hyperplasia is prevented by androgen binding to AR suppressing c-MYC transcription, resulting in G0 arrest/terminal differentiation independent of Rb, p21, p27, FoxP3, or down regulation of growth factors receptors and instead involves androgen-induced formation of AR/β-catenin/TCF-4 complexes, which suppress c-MYC transcription. Such suppression does not occur when AR is mutated in its zinc-finger binding domain. DISCUSSION: Proliferation of non-transformed human PrECs is dependent upon c-MYC transcription via formation/binding of β-catenin/TCF-4 complexes at both 5' and 3' c-MYC enhancers stimulated by Wnt-independent, PGF induced Akt signaling. In the presence of continuous PGF signaling, PrEC hyperplasia is prevented by androgen-induced formation of AR/β-catenin/TCF-4 complexes, which retains binding to 3' c-MYC enhancer, but now suppresses c-MYC transcription.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  TCF-4; androgen receptor; c-MYC, β-catenin; human prostate epithelial cells

Mesh:

Substances:

Year:  2014        PMID: 24913829      PMCID: PMC4856018          DOI: 10.1002/pros.22828

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  67 in total

1.  Antiandrogens prevent stable DNA-binding of the androgen receptor.

Authors:  Pascal Farla; Remko Hersmus; Jan Trapman; Adriaan B Houtsmuller
Journal:  J Cell Sci       Date:  2005-09-01       Impact factor: 5.285

2.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

3.  A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers.

Authors:  Gregory S Yochum; Colette M Sherrick; Mary Macpartlin; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

4.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

5.  Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

6.  E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model.

Authors:  Laura E Lamb; Beatrice S Knudsen; Cindy K Miranti
Journal:  J Cell Sci       Date:  2010-01-15       Impact factor: 5.285

7.  Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.

Authors:  Donald J Vander Griend; Jason D'Antonio; Bora Gurel; Lizamma Antony; Angelo M Demarzo; John T Isaacs
Journal:  Prostate       Date:  2010-01-01       Impact factor: 4.104

8.  Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.

Authors:  Lizhong Wang; Runhua Liu; Weiquan Li; Chong Chen; Hiroto Katoh; Guo-Yun Chen; Beth McNally; Lin Lin; Penghui Zhou; Tao Zuo; Kathleen A Cooney; Yang Liu; Pan Zheng
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

9.  Identification of a cell of origin for human prostate cancer.

Authors:  Andrew S Goldstein; Jiaoti Huang; Changyong Guo; Isla P Garraway; Owen N Witte
Journal:  Science       Date:  2010-07-30       Impact factor: 47.728

10.  Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.

Authors:  Jason M D'Antonio; Donald J Vander Griend; Lizamma Antony; George Ndikuyeze; Susan L Dalrymple; Shahriar Koochekpour; John T Isaacs
Journal:  PLoS One       Date:  2010-07-08       Impact factor: 3.240

View more
  31 in total

Review 1.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

2.  Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.

Authors:  Mark A White; Chenchu Lin; Kimal Rajapakshe; Jianrong Dong; Yan Shi; Efrosini Tsouko; Ratna Mukhopadhyay; Diana Jasso; Wajahat Dawood; Cristian Coarfa; Daniel E Frigo
Journal:  Mol Cancer Res       Date:  2017-05-15       Impact factor: 5.852

3.  Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone.

Authors:  Mindy Kim Graham; Lorenzo Principessa; Lizamma Antony; Alan K Meeker; John T Isaacs
Journal:  Prostate       Date:  2016-11-08       Impact factor: 4.104

4.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

5.  Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC).

Authors:  John T Isaacs; W Nathaniel Brennen; Samuel R Denmeade
Journal:  Ann Transl Med       Date:  2019-12

Review 6.  Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.

Authors:  Karim Zuhra; Fiona Augsburger; Tomas Majtan; Csaba Szabo
Journal:  Biomolecules       Date:  2020-04-30

7.  Molecular determinants of response to high-dose androgen therapy in prostate cancer.

Authors:  Michael D Nyquist; Alexandra Corella; Osama Mohamad; Ilsa Coleman; Arja Kaipainen; Daniel A Kuppers; Jared M Lucas; Patrick J Paddison; Stephen R Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  JCI Insight       Date:  2019-10-03

Review 8.  Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?

Authors:  John T Isaacs
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

9.  T-cell factor (TCF/LEF1) binding elements (TBEs) of FasL (Fas ligand or CD95 ligand) bind and cluster Fas (CD95) and form complexes with the TCF-4 and b-catenin transcription factors in vitro and in vivo which result in triggering cell death and/or cell activation.

Authors:  Xia Liu; Yuwei Huang; Yuanyuan Zhang; Xiaohong Li; Chun Liu; Shen Huang; Dezhi Xu; Yang Wu; Xiaojuan Liu
Journal:  Cell Mol Neurobiol       Date:  2016-04-18       Impact factor: 5.046

10.  Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling.

Authors:  Ruizhe Zhao; Xingjie Wang; Chenyi Jiang; Fei Shi; Yiping Zhu; Boyu Yang; Jian Zhuo; Yifeng Jing; Guangheng Luo; Shujie Xia; Bangmin Han
Journal:  Cell Prolif       Date:  2017-11-30       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.